Dr. Oppelt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110Phone+1 800-647-2098Fax+1 314-362-3192
Education & Training
- Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
- Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 2008 - 2012
- University of Missouri-Columbia School of MedicineClass of 2008
Certifications & Licensure
- IL State Medical License 2020 - 2026
- MO State Medical License 2015 - 2025
- OH State Medical License 2008 - 2016
Clinical Trials
Publications & Presentations
PubMed
- 1 citationsRisk Factors for Functional Outcomes in Advanced Laryngeal Squamous Cell Carcinoma.David S Lee, Jake J Lee, Parul Sinha, Sidharth V Puram, Ryan S Jackson
The Laryngoscope. 2023-03-01 - Bleeding pattern after medical management of early pregnancy loss with mifepristone-misoprostol and its prognostic value: a prospective observational cohort study.SH Enzelsberger, Daniela Wetzlmair, Philipp Hermann, Helga Wagner, Omar Shebl
Archives of Gynecology and Obstetrics. 2021-10-25 - 8 citationsIonophore application for artificial oocyte activation and its potential effect on morphokinetics: a sibling oocyte study.Omar Shebl, Philip Sebastian Trautner, Sabine Enengl, Elisabeth Reiter, C Allerstorfer
Journal of Assisted Reproduction and Genetics. 2021-10-13
Journal Articles
- Outcomes of Patients with Single-Node Metastasis of Human Papillomavirus–Related Oropharyngeal Cancer Treated with Transoral SurgeryPeter Oppelt, Kevin Palka, JAMA Otolaryngology–Head & Neck Surgery
Press Mentions
- Safety and Efficacy of Zimberelimab (AB122) in Combination with Domvanalimab (AB154) and Etrumadenant (AB928) in Patients with Previously Treated Non-Small Cell Lung CancerMarch 10th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: